Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Dietmar, Falke"'
Autor:
Matthias Müller, Manuel Pombo-Suarez, Ilona Steigerwald, Andreas Binder, Dietmar Falke, Lieven Kennes, Ralf Baron, Jan-Peter Jansen
Publikováno v:
Pain Practice. 16:600-619
Objective To evaluate tolerability, safety, and quality-of-life outcomes in non-opioid-pretreated patients with severe chronic low back pain with a neuropathic component receiving tapentadol PR vs. oxycodone/naloxone PR. Methods Eligible patients (av
Autor:
Dietmar Falke, Matthias Müller, Ilona Steigerwald, Ralf Baron, Cecile Dubois, Emilio Martín-Mola
Publikováno v:
Pain Practice. 15:455-470
Objective To evaluate the effectiveness and tolerability of tapentadol PR monotherapy versus tapentadol PR/pregabalin combination therapy for severe, chronic low back pain with a neuropathic component. Methods Eligible patients had painDETECT “uncl
Autor:
Ralf, Baron, Jan-Peter, Jansen, Andreas, Binder, Manuel, Pombo-Suarez, Lieven, Kennes, Matthias, Müller, Dietmar, Falke, Ilona, Steigerwald
Publikováno v:
Pain practice : the official journal of World Institute of Pain. 16(5)
To evaluate tolerability, safety, and quality-of-life outcomes in non-opioid-pretreated patients with severe chronic low back pain with a neuropathic component receiving tapentadol PR vs. oxycodone/naloxone PR.Eligible patients (average pain intensit
Autor:
Francisco J. Blanco, Matthias Müller, Dietmar Falke, Rudolf Likar, Ilona Steigerwald, Lieven Kennes, Emilio Martín-Mola, Ralf Baron
Publikováno v:
RUC. Repositorio da Universidade da Coruña
instname
Pain Practice
instname
Pain Practice
[Abstract] OBJECTIVE: To evaluate the effectiveness of tapentadol prolonged release (PR) vs. oxycodone/naloxone PR in non-opioid-pretreated patients with severe chronic low back pain with a neuropathic pain component. METHODS: Eligible patients (aver
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a2952c3099776c4fb4833d803941440
http://hdl.handle.net/2183/25268
http://hdl.handle.net/2183/25268
Publikováno v:
Pain practice : the official journal of World Institute of Pain. 15(5)
Objective To evaluate the effectiveness and tolerability of tapentadol prolonged release (PR) for severe, chronic low back pain with a neuropathic component in a subpopulation that achieved adequate pain relief with tapentadol PR 300 mg/day in a rand
Autor:
Ralf, Baron, Emilio, Martin-Mola, Matthias, Müller, Cecile, Dubois, Dietmar, Falke, Ilona, Steigerwald
Publikováno v:
Pain practice : the official journal of World Institute of Pain. 15(5)
To evaluate the effectiveness and tolerability of tapentadol PR monotherapy versus tapentadol PR/pregabalin combination therapy for severe, chronic low back pain with a neuropathic component.Eligible patients had painDETECT "unclear" or "positive" ra
Autor:
Dietmar, Falke, Rudy L, Juliano
Publikováno v:
Current opinion in molecular therapeutics. 5(2)
The prospect of selectively regulating gene expression is highly appealing, both for laboratory investigations and for potential therapeutic applications. This possibility has recently become a reality through the use of designed transcription factor
Publikováno v:
European Journal of Pain Supplements. 5:85-85
Publikováno v:
Clinical Drug Investigation
Background Tapentadol prolonged release (PR; 100–250 mg twice daily) has been efficacious and well tolerated for managing moderate-to-severe, chronic osteoarthritis hip or knee pain in phase 3 studies with washout of previous analgesic treatment. O